Inventory

12 Months Ended

Dec. 31, 2022

Inventory Disclosure [Abstract]

Inventory

5. Inventory

The Company's inventory balance consists of the following (in thousands):

	As of December 31,
	2021		2022
Raw materials	$	—	$	1,201
Work-in-process		—		29
Finished goods		—		—
	$	—	$	1,230

Inventory is stated at the lower of cost and net realizable value and consists of raw materials, work-in-process and
finished goods. The Company began capitalizing inventory costs following FDA approval of FUROSCIX in October 2022 and has not recorded any significant inventory write-downs since that time. The Company currently uses a limited number of third-party contract manufacturing organizations ("CMOs") to produce its inventory.